TBX18 Inhibitors
TBX18 inhibitors are a class of chemical compounds designed to selectively inhibit the activity of the TBX18 protein, a member of the T-box family of transcription factors. TBX18 plays an essential role in regulating gene expression during embryonic development, particularly in processes related to cell fate determination, organogenesis, and tissue patterning. Inhibition of TBX18 disrupts its ability to bind to specific DNA sequences, affecting the transcription of target genes that are critical for developmental signaling pathways. The regulation of these pathways by TBX18 is crucial for controlling differentiation and spatial organization of cells in early development, making its inhibition an effective approach for studying its role in these processes.
The chemical structure of TBX18 inhibitors is designed to specifically interfere with the DNA-binding domain of the TBX18 protein. These compounds often contain structural motifs that allow them to interact directly with the T-box domain, thereby preventing TBX18 from associating with its target DNA sequences. Through careful design and optimization, researchers develop inhibitors that can selectively target TBX18 without affecting other T-box family proteins, which share similar DNA-binding regions. The refinement of TBX18 inhibitors involves techniques like structure-activity relationship (SAR) studies, which help to improve binding affinity and specificity. These inhibitors are valuable tools in research to better understand the complex mechanisms of gene regulation controlled by TBX18, providing insight into its role in development and cellular differentiation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. TBX18 is known to be regulated through PI3K/AKT signaling pathways. Inhibition of PI3K can lead to reduced AKT phosphorylation, which in turn may inhibit TBX18 activity due to its involvement in the same cellular signaling network. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of ALK5, which is involved in TGF-β signaling. While TGF-β itself is not to be considered, the inhibition of its receptors, like ALK5, can influence downstream signaling pathways that may indirectly inhibit TBX18 activity due to their interconnected nature. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, specifically blocking the activation of MAPK/ERK. This inhibition can alter signaling pathways that intersect with those regulating TBX18, potentially leading to an indirect inhibiton of TBX18 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. The JNK pathway is involved in various cellular processes and can interact with signaling pathways associated with TBX18. Inhibiting JNK might lead to alterations in these pathways, indirectly inhibiting TBX18 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since TBX18 activity can be linked to the PI3K/AKT/mTOR pathway, inhibition of mTOR by Rapamycin could lead to changes in cellular signaling that indirectly inhibit TBX18 expression or activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor. Rho-associated protein kinase (ROCK) participates in pathways that may intersect with those involving TBX18. Inhibiting ROCK could indirectly inhibit TBX18 activity through changes in these interconnected signaling pathways. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Doramapimod is a p38 MAPK inhibitor. By inhibiting p38 MAPK, BIRB 796 can affect signaling pathways that are potentially linked to TBX18, thereby indirectly inhibiting its activity. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor. It specifically targets the MAPK/ERK pathway, potentially influencing TBX18 through indirect inhibition of signaling networks in which TBX18 is involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002. By inhibiting PI3K, it affects the PI3K/AKT pathway, which is related to TBX18 regulation. This can lead to an indirect inhibiton on TBX18 activity. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin is an AMPK inhibitor and also known to inhibit BMP signaling. These pathways can interact with those involving TBX18, so inhibiting them could indirectly inhibit TBX18 activity. | ||||||